Limits...
Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.

Drewes YM, Poortvliet RK, Blom JW, de Ruijter W, Westendorp RG, Stott DJ, Blom HJ, Ford I, Sattar N, Wouter Jukema J, Assendelft WJ, de Craen AJ, Gussekloo J - J Am Geriatr Soc (2014)

Bottom Line: Fatal and nonfatal CHD and mortality.In the placebo group, participants with a high homocysteine level (n = 588) had a 1.8 higher risk (95% confidence interval (CI) = 1.2-2.5, P = .001) of fatal and nonfatal CHD than those with a low homocysteine level (n = 597).With pravastatin treatment, this group has the highest absolute risk reduction and the lowest NNT to prevent fatal and nonfatal CHD.

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.

Show MeSH

Related in: MedlinePlus

Cumulative incidence of fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on baseline plasma levels of homocysteine in the placebo group (n = 1,764). HR = Hazard Ratio; CI = Confidence Interval: high versus low homocysteine group, adjusted for age.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4232895&req=5

fig01: Cumulative incidence of fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on baseline plasma levels of homocysteine in the placebo group (n = 1,764). HR = Hazard Ratio; CI = Confidence Interval: high versus low homocysteine group, adjusted for age.

Mentions: Figure 1 shows the cumulative incidence of fatal and nonfatal CHD and all-cause mortality for the three homocysteine groups in the placebo group. Participants with medium homocysteine levels had no greater risk of fatal and nonfatal CHD than those with low homocysteine (HR = 1.1, 95% CI = 0.76–1.6, P = .57), but those with high homocysteine had a 1.8 times greater risk (95% CI = 1.2–2.5, P = .001). For overall mortality, the HRs were 1.0 (95% CI = 0.67–1.5, P = .99) and 1.7 (95% CI = 1.2–2.5, P = .003), respectively. These estimates did not change after additional adjustments for history of CVD; Framingham risk factors; or CRP, HDL-C, and creatinine clearance (data not shown).


Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.

Drewes YM, Poortvliet RK, Blom JW, de Ruijter W, Westendorp RG, Stott DJ, Blom HJ, Ford I, Sattar N, Wouter Jukema J, Assendelft WJ, de Craen AJ, Gussekloo J - J Am Geriatr Soc (2014)

Cumulative incidence of fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on baseline plasma levels of homocysteine in the placebo group (n = 1,764). HR = Hazard Ratio; CI = Confidence Interval: high versus low homocysteine group, adjusted for age.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4232895&req=5

fig01: Cumulative incidence of fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on baseline plasma levels of homocysteine in the placebo group (n = 1,764). HR = Hazard Ratio; CI = Confidence Interval: high versus low homocysteine group, adjusted for age.
Mentions: Figure 1 shows the cumulative incidence of fatal and nonfatal CHD and all-cause mortality for the three homocysteine groups in the placebo group. Participants with medium homocysteine levels had no greater risk of fatal and nonfatal CHD than those with low homocysteine (HR = 1.1, 95% CI = 0.76–1.6, P = .57), but those with high homocysteine had a 1.8 times greater risk (95% CI = 1.2–2.5, P = .001). For overall mortality, the HRs were 1.0 (95% CI = 0.67–1.5, P = .99) and 1.7 (95% CI = 1.2–2.5, P = .003), respectively. These estimates did not change after additional adjustments for history of CVD; Framingham risk factors; or CRP, HDL-C, and creatinine clearance (data not shown).

Bottom Line: Fatal and nonfatal CHD and mortality.In the placebo group, participants with a high homocysteine level (n = 588) had a 1.8 higher risk (95% confidence interval (CI) = 1.2-2.5, P = .001) of fatal and nonfatal CHD than those with a low homocysteine level (n = 597).With pravastatin treatment, this group has the highest absolute risk reduction and the lowest NNT to prevent fatal and nonfatal CHD.

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands.

Show MeSH
Related in: MedlinePlus